hiv disease News
-
Findings from Cornell University College of Medicine in HIV/AIDS Reported
Investigators discuss in "a(1)Proteinase Inhibitor Regulates CD4 Lymphocyte Levels and Is Rate Limiting in HIV-1 Disease" new findings in HIV/AIDS. According to the authors of recent research from New York City, New York, "The regulation of adult stem cell migration through human hematopoietic tissue involves the chemokine CXCL12 (SDF-1) and its receptor CXCR4 (CD184). In addition, human ...
-
BIO CEO Defends Dr. Fauci, Says Criticisms `Undermine Our Response to this Pandemic`
In response to attacks on Dr. Anthony Fauci’s credibility and character, BIO President and CEO Dr. Michelle McMurry-Heath issued the following statement: “As this global pandemic continues to wreak havoc, we must stand behind the scientists and researchers working tirelessly to eradicate this devastating disease. Nothing is more disheartening or disturbing than to see Dr. Anthony ...
-
Frontier Biotechnologies` First Long-acting Injectable (Aikening(R), in a Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients
The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies TALENT is the world's first phase III clinical trial of the new long-acting HIV-1 fusion inhibitor, Aikening® (generic name: Albuvirtide [ABT]) in an all-Asian population TALENT ...
-
Scientists create first map of global emerging disease hotspots
In a paper published by the leading scientific journal Nature, scientists at the Consortium for Conservation Medicine (CCM) Wildlife Trust New York, the Zoological Society of London (ZSL), Columbia University (New York) and the University of Georgia have announced a major breakthrough in the understanding of what causes diseases like HIV/AIDS and SARS to emerge, and how to further predict and ...
-
Peptides for Diabetes Research—a Special Offer of BOC Sciences
BOC Sciences has been constantly enriching its peptide product library for years. Its peptides for diabetes research are recently brought into focus due to the growing concerns on this problem According to data from the WHO, a large number of adults are having diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia. The absolute lack of insulin, due to destruction of the ...
By BOC Sciences
-
NanoPin Technologies Founder`s Study Demonstrates Greater Accuracy in Detecting TB in Infants
NanoPin Technologies Inc, a biotechnology company focused on developing advanced diagnostics to improve the lives of millions of individuals affected by infectious diseases worldwide, announced the release of a scientific study conducted by founder Tony Hu, Ph.D. Dr. Hu is a professor and Weatherhead Presidential Chair in Biotechnology Innovation at the Tulane University School of Medicine. ...
-
World Health Day: Commission highlights solidarity in health
To mark World Health Day, European Commissioner for Health, Androulla Vassiliou visited several community health projects in Kenya on 6 and 7 April. These projects promote social and economic development through poverty alleviation and strengthening health and education. Improving health conditions and strengthening access to healthcare are important objectives for the European Union, both for ...
-
Velano raises $15M to go beyond non-invasive blood tests
For most of us, getting blood drawn is an unpleasant, but necessary, part of life. For others, though, it’s extremely risky, if not impossible. Those people have what is known as difficult venous access (DVA), and they can include children, people witjh chronic illnesses, the elderly and people with diabetes, among others. Velano Vascular is a company that has developed a way to draw blood ...
-
Lauren Sciences independently recognized as a Technology Innovator in Drug Delivery with its V-Smart Platform, and selected as a Featured Company, in new report by MCD Group
New York, N.Y., June 18, 2013 -- Lauren Sciences, a privately-held biotechnology company furthering development of its novel V-Smart™ nanovesicle platform technology, announced today that it was independently recognized as a Technology Innovator in Drug Delivery with its V-Smart™ Platform, and selected as a Featured Company, in a new report by MCD Group. The report, "Early Stage Drug ...
-
At UN, global leaders commit to act on antimicrobial resistance
World leaders today signalled an unprecedented level of attention to curb the spread of infections that are resistant to antimicrobial medicines. Antimicrobial resistance (AMR) happens when bacteria, viruses, parasites, and fungi develop resistance against medicines that were previously able to cure them. For the first time, Heads of State committed to taking a broad, coordinated approach to ...
-
Lauren Sciences LLC research team at Ben-Gurion University awarded grant from The ALS Association to develop V-Smart Therapeutic for ALS
New York, N.Y., August 12, 2014 -- Lauren Sciences LLC, the private New York biotechnology company developing transformative V-Smart™ therapeutics, with its innovative V-Smart™ targeted drug delivery system, based upon its novel V-Smart™ nanovesicle platform technology, announced the award of a grant today from The ALS Association to its research team at Ben-Gurion University. ...
-
Streptococcus pneumoniae Exposed in New Online Video
Today, the IAQ Video Network and Cochrane & Associates announced the release of another online video to help educate the public about issues that may impact their health. The latest educational video discusses Streptococcus pneumoniae infections and how they may impact human health. Streptococcus pneumoniae, or pneumococcus, is a type of Gram-positive bacteria. It can often be found in ...
-
Lauren Sciences LLC research team at Ben-Gurion University successfully completes Campbell Foundation 1-year grant to develop V-Smart therapeutic for neuro-HIV
New York, N.Y., October 22, 2013 -- Lauren Sciences LLC, a privately-held biotechnology company furthering development of V-Smart™ therapeutics based upon its novel nanovesicle platform technology, announced today successful completion by its research team at Ben-Gurion University of the first stage of developing a V-Smart™ therapeutic for the treatment of neuro-HIV. The development ...
-
BOC Sciences August Promotion: Compound Docking Solutions for Drug Discovery
As the leading expert in computer-aided drug discovery, BOC Sciences has developed compound docking technologies to facilitate the discovery of novel ligands for over 30 targets. Has compound docking ever brought us medicine? This was generally questioned in the pharmaceutical industry. With many innovators like BOC Sciences springing up and improvements being made in computational chemistry, ...
By BOC Sciences
-
Biomed Analysis: Sustainability goals too light on health
The proposed Sustainable Development Goals need more focus on health to continue the progress achieved with MDGs, argues Priya Shetty. Since 2000, global health efforts have been aligned to the aims of the Millennium Development Goals (MDGs). Indeed, the link has been so close that some public health experts have voiced concern that health goals not specified in the MDG manifesto, such as ...
By SciDev.Net
-
MOBILion and International Research Team are Awarded Grant from The Michael J. Fox Foundation and the Shake it Up Australia Foundation to Resolve Biomarkers for Parkinson’s Disease
MOBILion Systems, Inc., a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and therapeutic development, is collaborating with an international research team to identify alterations in the metabolism of selective glycosphingolipids in specific brain regions that contribute to the early onset and progression of Parkinson’s disease. The ...
-
Preventing Outbreaks of Streptococcus pneumoniae Infections
Until 2000, Streptococcus pneumoniae infections caused 100,000-135,000 hospitalizations for pneumonia, 6 million cases of ear infections, and 60,000 cases of invasive disease, including 3300 cases of meningitis. Disease figures have improved since a pneumococcal conjugate vaccine was introduced in 2001. Streptococcus pneumoniae, or pneumococcus, is a type of Gram-positive bacteria. It can ...
-
BOC Sciences Outlines Its Contribution of Peptides to Cardiovascular Research
BOC Sciences' monthly report released in August showed that its peptide products had vastly facilitated the R&D of cardiovascular therapies. February is set as American Heart Month since heart disease is the number one cause of death for most groups, affecting all ages, genders, and races. More than 600,000 Americans die from heart disease every year. The striking fact drives a great deal ...
By BOC Sciences
-
BOC Sciences: Peptides Open New Path toward Osteoporosis Treatment
BOC Sciences declares that some of its peptide products have been proven applicable for osteoporosis treatment, which is a significant contribution to the therapeutic areas. Bone tissue engineering and the research surrounding peptides have expanded significantly over the last few decades. Several peptides have been shown to support and stimulate the bone healing response and have been proposed ...
By BOC Sciences
-
Pascal Biosciences Confirms Specific Cannabinoids Combat Coronavirus
SEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 23, 2020 – Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) today announced the Company has confirmed an earlier report that certain cannabinoids block replication of SARS-CoV-2, the coronavirus that causes COVID-19. Four different laboratories have now experimentally verified ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you